Spinoff deepCDR Biologics acquired by Boston-based company Alloy Therapeutics

The D-BSSE spinoff deepCDR Biologics, which originated from the Laboratory of Systems and Synthetic Immunology of Sai Reddy, has become part of Alloy Therapeutics, a biotechnology company specialised in antibody drug discovery. The acquisition of deepCDR will add expertise in bioinformatics and machine learning to Alloy’s antibody discovery process and workflow. The deepCDR team will remain in Basel and will turn into a permanent Alloy research site.